



# SITUATION REPORT

## Nigeria Centre for Disease Control and Prevention

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDcGov

<b>TITLE:</b>	<b>UPDATE ON MPOX (MPX) IN NIGERIA</b>
<b>SERIAL NUMBER:</b>	<b>3</b>
<b>EPI-WEEK:</b>	<b>3</b>
<b>DATE:</b>	<b>January 22, 2023</b>


**Table 1 – Key Indicators**

Reporting year	Reporting week	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023 Current	Week 3	79	11	0	0.0	7 + FCT	8
2023 Cumulative	Week 1-3	134	24	1	4.2	11 + FCT	19
2022 Cumulative	Week 1-3	4	3	0	0.0	2	2


### Highlights

- In week 3, the number of new suspected cases was 79, compared with 34 cases reported in week 2, 2023. These were reported from twenty-two (22) states and FCT – Ogun (10), Abia (9), Lagos (8), Ondo (7), Bayelsa (6), Imo (5), Enugu (4), FCT (4), Kwara (4), Adamawa (3), Kaduna (3), Cross River (2), Delta (2), Ekiti (2), Nasarawa (2), Akwa Ibom (1), Borno (1), Edo (1), Osun (1), Oyo (1), Rivers (1), Sokoto (1) and Taraba (1) across 42 Local Government Areas.
- Since week 1 of 2023, eleven (11) states and FCT have recorded at least one confirmed Mpox case across nineteen (19) Local Government Areas. Since the beginning of 2023, the States with the highest-burden are Lagos (25.0%), Abia (16.7%), FCT (12.5%), Borno (8.3%) and Imo (8.3%), contributing 70.8% of confirmed cases.
- The number of confirmed cases is eleven (11) in week 3, 2023, compared with ten (10) confirmed cases reported in week 2, 2023.
- No death was recorded in week 3, with a CFR of 0.0% compared with 7.7% of CFR that was reported in week 2, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 2769 suspected cases have been reported from 36 states and FCT in the country. Of these 2769 suspected cases, 1012 (36.5%) were confirmed (with males predominantly affected) from 34 states and FCT. Sixteen (16) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues coordinating the response activities at all levels.






**Figure 1:** Epidemic curve of suspected and confirmed Mpox cases January 2023 till date





**Figure 2:** Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date



**Figure 3:** Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date

**Figure 4:** Area chart for States showing the trend in suspected and confirmed Mpox cases in highest burden States from January 2023 till date





**Figure 5:** Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 22<sup>nd</sup> January 2023

**Table 1:** Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 22<sup>nd</sup> January 2023

Reporting year	Suspected cases	Confirmed cases	Deaths (Confirmed cases)	Case Fatality Ratio (CFR)	States Affected (Confirmed cases)	LGAs Affected (Confirmed cases)
2023	134	24	1	4.2	11 + FCT	19
2022	2123	762	7	0.9	34 + FCT	238
2021	98	34	0	0.0	8 + FCT	25
2020	35	8	0	0.0	5	7
2019	65	47	1	2.1	11	26
2018	116	49	1	2.0	13	25
2017	198	88	6	6.8	14 + FCT	33

**Table 2:** Age distribution of cumulative number of confirmed Mpox cases September 2017 – 22<sup>nd</sup> January 2023

Age Group	2017	2018	2019	2020	2021	2022	2023	Total
0-10 Years	7	5	1	0	1	125	4	143
11-20 Years	12	4	1	0	4	123	2	146
21-30 Years	34	13	13	4	10	187	6	267
31- 40 Years	26	17	22	4	13	205	5	292
41-50 Years	9	10	9	0	5	89	5	127
>50 Years	0	0	1	0	1	33	2	37
<b>Total</b>	<b>88</b>	<b>49</b>	<b>47</b>	<b>8</b>	<b>34</b>	<b>762</b>	<b>24</b>	<b>1012</b>

**Table 3:** Nigeria Confirmed Mpox cases by State, September 2017 – 22<sup>nd</sup> January 2023

S/N	State	2017	2018	2019	2020	2021	2022	2023	Total
1	Lagos	4	1	15	4	6	188	6	224
2	Rivers	25	14	7	1	5	37	0	89
3	Bayelsa	19	11	7	0	6	45	1	89
4	Abia	1	2	0	0	0	58	4	65
5	Delta	3	6	10	1	9	31	0	60
6	Imo	5	2	1	0	0	45	2	55
7	Ogun	0	0	0	0	1	40	1	42
8	Ondo	0	0	0	0	0	40	0	40
9	Edo	4	1	1	0	4	27	0	37
10	FCT	5	0	0	0	1	25	3	34
11	Anambra	0	1	1	0	0	25	0	27
12	Cross River	9	3	1	0	1	12	0	26
13	Kwara	0	0	0	0	0	21	0	21
14	Plateau	0	2	0	1	0	16	0	19
15	Akwa Ibom	6	0	1	0	0	12	1	20
16	Nasarawa	1	1	0	0	0	17	1	20
17	Adamawa	0	0	0	0	0	16	0	16
18	Oyo	1	3	2	0	0	10	0	16
19	Kaduna	0	0	0	0	0	15	1	16
20	Ebonyi	0	0	0	1	0	12	0	13
21	Benue	2	0	0	0	0	10	0	12
22	Borno	0	0	0	0	0	11	2	13
23	Enugu	1	2	1	0	0	4	1	9
24	Katsina	0	0	0	0	0	8	0	8
25	Taraba	0	0	0	0	0	7	0	7
26	Kano	0	0	0	0	0	7	0	7
27	Gombe	0	0	0	0	0	6	0	6
28	Kogi	0	0	0	0	0	5	1	6
29	Osun	0	0	0	0	0	5	0	5
30	Ekiti	2	0	0	0	0	1	0	3
31	Niger	0	0	0	0	1	1	0	2
32	Kebbi	0	0	0	0	0	2	0	2
33	Bauchi	0	0	0	0	0	1	0	1
34	Zamfara	0	0	0	0	0	1	0	1
35	Yobe	0	0	0	0	0	1	0	1
	<b>Grand Total</b>	<b>88</b>	<b>49</b>	<b>47</b>	<b>8</b>	<b>34</b>	<b>762</b>	<b>24</b>	<b>1012</b>

## Response activities

Pillar	Activities to date	Next steps
<b>Coordination</b>	<ul style="list-style-type: none"> <li>Ensuring the smooth running of the activities of the National Mpox Emergency Operations Centre (EOC)</li> </ul>	<ul style="list-style-type: none"> <li>Engage with states to collate their challenges with Mpox case detection, reporting and response</li> </ul>
<b>Surveillance</b>	<ul style="list-style-type: none"> <li>There are no deaths reported in the current week</li> <li>Three (3) states have incomplete key information in the case investigation forms (sex, age, date of symptoms onset)</li> <li>No information on Mpox case contacts SORMAS</li> </ul>	<ul style="list-style-type: none"> <li>Follow-up with Enugu, Ekiti and Lagos States to update missing details on the case investigation forms</li> <li>Employ all reporting states to update details of follow-up contact on SORMAS</li> </ul>
<b>Laboratory</b>	<ul style="list-style-type: none"> <li>Onboarded a new third-party logistics firm for sample transportation within the NCDC laboratory networks including Mpox</li> <li>The sample positivity rate for Mpox is 15% and 79% for Varicella-zoster virus (VZV)</li> <li>Four (4) cases have co-infection of Mpox and VZV</li> <li>24% of samples met the target overall turnaround time (time sample collected from states to time result shared to states)</li> </ul>	<ul style="list-style-type: none"> <li>Continue to engage with new third-party logistics to improve overall turnaround time for Mpox samples</li> <li>Hold meeting with identified States to sort out issues affecting external turnaround time</li> </ul>
<b>Case management</b>	<ul style="list-style-type: none"> <li>Following up with all positive cases at the state level</li> <li>The mortality review found that the case from Enugu that died had Mpox VZV co-infection and organ failure at the tertiary; no information on HIV status</li> </ul>	<ul style="list-style-type: none"> <li>Finalise Mpox case management guidelines</li> </ul>
<b>IPC</b>	<ul style="list-style-type: none"> <li>Reviewing the Mpox IPC guidelines for home care</li> </ul>	<ul style="list-style-type: none"> <li>Finalize IPC IEC materials in collaboration with BA-N, MTaPS and Risk comms pillar</li> </ul>
<b>Risk communication</b>	<ul style="list-style-type: none"> <li>Airing jingles in Lagos and FCT</li> </ul>	<ul style="list-style-type: none"> <li>Continue to engage with the public via NCDC social media with key messages on Mpox</li> </ul>

## Notes on this report

### **Data Source**

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

### **Case definitions**

#### *Suspected case*

- An acute illness with fever  $>38.3^{\circ}\text{C}$ , intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand

#### *Probable case*

- A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case

#### *Confirmed case*

- A clinically compatible case that is laboratory confirmed

#### *Contact*

- Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

#### *Calculations*

- Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.